This inventor holds 32 USPTO granted patents. Top assignees: Bayer Aktiengesellschaft, Baker Aktiengesellshaft, Wayne State University. Active years: 1976-1988.
Company Filing History:
30 out of 12,266 
1 out of 1 
1 out of 602 
Years Active: 1976-1988
Areas of Expertise:
Title: Eike Moller: Innovator in Cancer Treatment
Introduction
Eike Moller, a prolific inventor based in Wuppertal, Germany, holds an impressive portfolio of 32 patents. His contributions to the field of medical innovations, particularly in cancer treatment, have significantly advanced therapeutic methodologies.
Latest Patents
Among his latest patents, Moller has developed a method for treating human tumor cell metastasis. This therapeutic approach focuses on administering a therapeutically effective amount of 3-methyl-1-[2-(2-naphthyloxy)-ethyl]-2-pyrazolin-5-one or its pharmaceutically acceptable salt. Additionally, he has patented new imidazoazole-alkenoic acid amide compounds, describing their production methods and their applications in medical compositions. This invention also includes carbonyl compounds and alkenoic acids as intermediates, further showcasing his innovative approach to cancer therapies.
Career Highlights
Eike Moller has made significant strides in his career, having worked with renowned organizations such as Bayer Aktiengesellschaft and Wayne State University. His work in these institutions has been instrumental in the advancement of research in pharmaceuticals, particularly in oncology.
Collaborations
Throughout his career, Moller has collaborated with notable professionals in his field, including Harald Horstmann and Egbert Wehinger. His partnerships with such expertise have fostered fruitful innovation and development of groundbreaking therapies.
Conclusion
Eike Moller’s dedication to medical innovation is evident through his extensive patent portfolio and collaborations with distinguished institutions and professionals. His work continues to influence the landscape of cancer treatment, illustrating the impact of innovative thinking and collaboration in the field of pharmaceuticals.